# Characterizing and Predicting Drug Effects on Cognition

> **NCT01889602** · PHASE4 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 60 (actual)

## Conditions studied

- Cognitive Deficits

## Interventions

- **DRUG:** Lorazepam
- **OTHER:** Placebo
- **DRUG:** Topiramate 100mg
- **DRUG:** Topiramate 150mg
- **DRUG:** Topiramate 200mg

## Key facts

- **NCT ID:** NCT01889602
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01889602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01889602, "Characterizing and Predicting Drug Effects on Cognition". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01889602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*